Thrombotic cardiovascular disease, including acute myocardial infarction, ischemic stroke,
and venous thromboembolic disease, is the leading cause of morbidity and mortality …

Cardiovascular thrombotic disease is an underlying cause of stroke, myocardial infarction
and pulmonary embolism–some of the leading causes of death worldwide. Reperfusion …

Thromboembolic conditions are a leading cause of death worldwide, and deep vein
thrombosis (DVT), or occlusive venous clot formation, is a critical and rising problem that …

The first-line treatment for non-Hodgkin's lymphoma is chemotherapy. While generally well
tolerated, off-target effects and chemotherapy-associated complications are still of concern …

Drug delivery systems are required for drug targeting to avoid adverse effects associated
with chemotherapy treatment regimes. Our approach is focused on the study and …

Clinical use of tissue plasminogen activator (tPA) in thrombolytic therapy is limited by its
short circulation time and hemorrhagic side effects. Inspired by fibrinogen binding to …

A thrombus is a blood clot that forms in the lumen of an artery or vein, restricting blood flow
and causing clinical symptoms. Thrombosis is associated with many life‐threatening …

Arterial and venous thrombosis are among the most common causes of death and
hospitalization worldwide. Nanotechnology approaches hold great promise for molecular …

Understanding the pharmacokinetics, blood compatibility, biodistribution and clearance
properties of nanoparticles is of great importance to their translation to clinical application. In …

Aim: To develop a fibrin-specific urokinase nanomedicine thrombolytic agent. Materials &
Methods: In vitro fibrin-clot dissolution studies were utilized to develop and characterize …